Loading organizations...
§ Private Profile · 4539 Metropolitan Ct, Frederick, Maryland, 21704, United States
Veralox Therapeutics is a technology company.
Veralox Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics. It targets the 12-lipoxygenase (12-LOX) pathway to address underlying pathologies of serious immuno-inflammatory diseases. This approach informs novel treatments, including their selective 12-LOX inhibitor, VLX-1005, designed to modulate critical immune signaling.
Operating as a drug discovery and development entity, Veralox Therapeutics is based in Frederick, Maryland. The company was founded on the insight that specific 12-LOX inhibition could provide effective therapies for complex inflammatory conditions. Public information lacks specific founder names or exact founding dates.
Veralox’s therapeutics are intended for patients suffering from life-threatening immuno-inflammatory diseases, initially focusing on heparin-induced thrombocytopenia. The company’s vision is to pioneer new classes of medicines, intervening at fundamental disease progression points. This aims to deliver targeted, small molecule solutions for significant unmet medical needs in inflammatory and thrombotic disorders.
Veralox Therapeutics has raised $70.0M across 4 funding rounds.
Veralox Therapeutics has raised $70.0M in total across 4 funding rounds.
Veralox Therapeutics has raised $70.0M in total across 4 funding rounds.
Veralox Therapeutics's investors include Genesys Capital, Hatteras Venture Partners, JDRF T1D Fund, Meg Wood, Peter Young, Sanofi Ventures, T1D Fund, NYBC Ventures, Pappas Capital, Alexandria Venture Investments, Jamie Stiff, Maryland Momentum Fund.
Veralox Therapeutics has raised $70.0M across 4 funding rounds. Most recently, it raised $24.0M Other Equity in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 20, 2023 | $24M Venture Round | — | Genesys Capital, Hatteras Venture Partners, JDRF T1D Fund, MEG Wood, Peter Young, Sanofi Ventures | Announced |
| Jun 1, 2023 | $24M Series U | — | Hatteras Venture Partners, T1D Fund, Genesys Capital, JDRF T1D Fund, Nybc Ventures, Pappas Capital, Sanofi Ventures | Announced |
| Jun 1, 2021 | $17M Series A | Hatteras Venture Partners | T1D Fund, Alexandria Venture Investments, Jamie Stiff, Maryland Momentum Fund, Point Field Partners, Sanofi Ventures, TEDCO, VTC Innovation Fund | Announced |
| Sep 1, 2019 | $5M Seed | Daniel Mansuri, VTC Ventures | Hatteras Venture Partners, T1D Fund, Maryland Momentum Fund, TEDCO, University OF Vermont Health Network | Announced |
Veralox Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics targeting underlying pathologies of immune-mediated and inflammatory diseases, particularly heparin-induced thrombocytopenia and thrombosis (HIT/T), type 1 diabetes (T1D), and related rare blood disorders.[1][2][3] Its lead candidate, VLX-1005, a selective 12-LOX inhibitor, addresses unmet needs in HIT/T patients and received FDA Fast Track designation after favorable Phase 1 results in 2022; the company serves patients with these conditions through innovative drug discovery accelerated by expert founders.[1][2][4] With $16.6M in total funding, Veralox demonstrates growth momentum as a private firm backed by investors like Pappas Capital and Genesys Capital, focusing on thrombosis and immuno-inflammatory therapies impacting hundreds of thousands annually.[2][3][5]
Veralox Therapeutics, LLC launched in 2017 (with some sources noting 2018) in Frederick, Maryland, founded by drug discovery and development experts from Avalon, Human Genome Sciences, and NIH/NCATS, bringing proven commercialization success.[1][2] The idea emerged from their deep expertise in small molecule innovation to tackle unmet needs in immune-mediated diseases, leading to the rapid development of VLX-1005 for HIT/T—a condition with limited treatments—and expansion to T1D and other inflammatory disorders.[1][2][3] Early traction included securing $16.6M in funding, advancing to clinical stage, and achieving positive Phase 1 data by 2022, marking pivotal milestones under CEO Jonathan Mow.[2][4]
Veralox rides the wave of precision medicine in immunology and hematology, targeting rare but devastating diseases like HIT/T amid rising demand for small molecule therapies in immune-inflammatory spaces.[1][2][6] Timing aligns with FDA incentives like Fast Track for orphan indications and growing venture interest in biotech post-2020 funding surges, fueled by advances in molecular pathway understanding (e.g., 12-LOX inhibition).[2][4] Market forces favoring Veralox include high unmet needs in thrombosis (hundreds of thousands affected yearly) and T1D, plus biotech hubs like Maryland's ecosystem via Maryland Momentum Fund.[3] It influences the landscape by pioneering selective inhibitors, potentially setting paradigms for immuno-hematologic treatments and attracting follow-on innovation in rare disease drug development.[1][5][7]
Veralox is poised for Phase 2/3 trials of VLX-1005, leveraging Fast Track momentum toward potential approvals in HIT/T, with pipeline expansion into T1D signaling broader immuno-inflammatory ambitions.[2][4] Trends like AI-driven drug discovery and orphan drug incentives will shape its path, amplifying efficiency in small molecule development amid biotech M&A waves. Its influence may grow through partnerships or acquisition by big pharma seeking rare disease assets, solidifying its role as a Frederick biotech leader—echoing its founding mission to accelerate first-in-class therapies for the underserved.[1][5]